Tag: Problems

Categories
Business

U.S. Home lawmakers search Boeing, FAA data after manufacturing issues

U.S. House lawmakers seek Boeing, FAA records after production problems

A Boeing logo is on the fuselage of a Boeing 787-9 Dreamliner aircraft manufactured by Boeing Co. on display ahead of the opening of the Farnborough International Airshow in Farnborough, UK on Sunday 13 July 2014.

Simon Dawson / Bloomberg

Two key House Democrats are soliciting records from Boeing and the Federal Aviation Administration after discovering production problems with the company’s 737 Max and 787 Dreamliner aircraft.

Rep. Peter DeFazio, D-Ore., Chair of the Transportation Committee, and Rick Larsen, D-Wash., Chair of the Aviation Sub-Committee, requested a list and descriptions of FAA inspections at the 737 manufacturing facility in Renton, Wash., Since 2017 and the Dreamliner South Carolina factory since 2015, according to a letter they sent to Dave Calhoun, CEO of Boeing, Tuesday that has been audited by CNBC.

Among other things, they requested records of supervision, the results of audits and the number of Boeing employees assigned to perform supervisory tasks at each location.

“While it is important that Boeing continue to voluntarily report such issues to the FAA, we are concerned that even after the longest civil airliner establishment in history, persistence of quality control and manufacturing defects – in two different cases – aircraft programs – remain “wrote the legislature. “This naturally raises questions about whether the FAA adequately oversees Boeing’s commercial aircraft programs, as well as Boeing’s internal quality controls and safety culture.”

The request comes less than a year after a report by the House Committee on Transportation and Infrastructure informed Boeing about the design and development of the 737 Max and the FAA for oversight failures. Two of these planes crashed between October 2018 and March 2019, killing all 346 people on the flights.

Boeing said last year it found the wrong clearance in some areas of the 787 fuselage. After inspections and a five-month break, delivery of the wide-body aircraft resumed in March. Regardless, an electrical issue with Boeing’s best-selling 737 Max grounded more than 100 aircraft in April, despite the FAA approving a solution last week.

Legislators asked for replies by June 8, but said that “continued production of these records will be considered if you cannot fully complete your answer by that date”.

A Boeing spokesman said the company is looking into the request.

The FAA did not respond immediately.

The agency announced last month that it was reviewing Boeing’s process for minor design changes, as well as the causes of the electrical problem on the 737 Max. This problem is not related to the system involved in the two major crashes.

Categories
Health

India Covid disaster exhibits public well being neglect, issues, underinvestment

India Covid crisis shows public health neglect, problems, underinvestment

A family waits in an ambulance with a patient who tests positive for COVID-19 to be admitted to hospital in Kolkata, India on May 10, 2021.

Debarchan Chatterjee | NurPhoto | Getty Images

World attention is now turning to India, the epicenter of the global pandemic, as the country battles a deadly second wave of Covid-19.

The unfolding human tragedy has exposed the deeply ingrained problems of the Indian health system after decades of neglect and underinvestment.

The crisis has brought India’s public health system to its knees. Scenes of hospitals running out of beds and people desperate for life-saving oxygen or critical medical care for their loved ones have made international headlines.

Low health care allocations

Since its independence in 1947, health has not been seen as an economically productive expense in the country for a long time – as opposed to investing in industry, agriculture and service sectors, K Srinath Reddy, president of the Public Health Foundation of India, told CNBC.

“For several decades, India’s health systems have not received the respect and resources they deserve. Public health funding has stagnated at around 1% of GDP and out-of-pocket health spending has been over 60% even in recent years” he said in an email. “The central government, as well as most of the state governments, had low budget allocations for health.”

India’s health spending is comparatively much lower than in many other countries.

The US spent almost 17% of its gross domestic product on public health care in 2018, while France and Germany spent more than 11% of GDP this year, according to the World Bank.

In a comparison of India with the other BRICS countries – Brazil, Russia, India, China and South Africa – India spent the least on health care in 2018. Brazil spent 9.5% of its GDP on health care that year, South Africa spent 8.1%, Russia 5.3% and China spent 5.35%.

India is now the second worst infected country in the world, just behind the United States.

The South Asian nation has reported more than 300,000 new infections per day in the past few weeks. According to the Ministry of Health, cumulative Covid infections reached almost 24.7 million on Sunday with more than 270,284 deaths.

However, health experts warn that the numbers are likely to be grossly underreported and the true extent of Covid infections and the number of people may never be officially known.

In a recent report by Fitch Solutions, the research firm said that despite several health reforms, India remains ill-positioned to tackle the rapid spread of the pandemic.

“With 8.5 hospital beds per 10,000 inhabitants and 8 doctors per 10,000, the country’s health sector is not prepared for such a crisis. Furthermore, the significant inefficiency, dysfunction and acute shortages of health systems in the public sector do not exist to meet the growing needs of the population “added the report.

The numbers are grim for a country like India with 1.4 billion people, which makes up 18% of the world’s population.

Lack of political will

India’s second wave started around February and accelerated through March and April. The virus spread quickly due to complacency with wearing masks at religious festivals and political rallies that drew large crowds in different parts of the country.

While the pandemic has highlighted the structural weaknesses of India’s public health system, those issues have always been there, Chandrakant Lahariya said. a Expert in medical public policy and health systems based in New Delhi.

I believe that after the long and excruciating pandemic, the political will is now stronger.

Chandrakant Lahariya

Expert in medical public order and health systems

He said this was mainly due to a lack of political will from successive political parties and the government, which had the power not to make public health a priority.

“Public health has never been a political priority or an election agenda,” he said. “Through the hands-off approach, the government has been sending a kind of message that health is an individual responsibility. People are unaware that elected governments and political leaders should be accountable and accountable to ensuring health services.”

This is where the problem arises, noted Lahariya.

“It has allowed the private health sector to grow by leaps and bounds while the public sector remains underfunded and underperforming,” he said in an email. “Now we are in this situation.”

Few Indians have health insurance

India’s private hospitals are largely commercialized and for-profit, and focus on treating disease. What makes matters worse is that the majority of Indians do not have health insurance and pay for health care out of their own pocket.

According to the Fitch report, more than 80% of the Indian population still has no significant health insurance coverage and around 68% have limited or no access to essential medicines.

While a pandemic can overwhelm almost any health system, including the best-equipped, the current situation in India was not inevitable, noted Vageesh Jain, a trained public health doctor in the UK

“The fundamental problem remains that the commercially operated private hospital system does not aim to provide long-term care to people to prevent and control disease,” said Jain, who is currently working with Public Health England on health protection in response to Covid-19.

Given the complex and multi-agency solutions, it is difficult to address such issues in any context, he added.

“But it is especially difficult in India, where there may be other quick public policy wins that are more deserving of immediate attention,” he argued.

A wake-up call for India?

India’s Prime Minister Narendra Modi has been widely criticized for failing to act earlier to suppress the virus resurgence.

In a rare reprimand, the British medical journal The Lancet recently beat up the Modi government for squandering early successes in controlling Covid and “presiding over a self-inflicted national disaster”.

“I believe that the political will is now stronger after the long and excruciating pandemic,” said Reddy of the Public Health Foundation of India. He added that the latest central budget and the Finance Commission’s recommendations are positive indicators.

The devastating situation caused by the ongoing wave is likely to be forgotten. But it must not be forgotten.

When the budget was announced in February, Indian Finance Minister Nirmala Sitharaman proposed that spending on health and wellbeing in India should more than double to $ 30.1 billion (rupees 2.2 trillion).

This includes strengthening national institutions and creating new institutions to identify and cure new diseases. There is also a new federal system in place to develop the country’s capacity for primary, secondary and tertiary care.

However, whether the crippling crisis will be a wake-up call for India to take its public health seriously remains to be seen, experts say.

“With this ongoing pandemic, the memories of the public and policymakers will last stronger and longer. Even after the pandemic has ended, it is a constant reminder that if We don’t invest, the economy will continue to slide on the banana peels of public health failure in public health and in strong health systems, “Reddy said.

Lahariya added that India has seen many public health disasters and emergencies. But most have resulted in very little, if any, changes in health systems.

“The time has come for India to have solid accountability of citizens to elected leaders. Questions should be asked of the people who elect them. Then only we can expect change,” he said.

“The devastating situation caused by the ongoing wave is likely to be forgotten. But it should not be forgotten.”

Categories
Health

Biden-backed Covid vaccine patent waiver will trigger issues

Biden-backed Covid vaccine patent waiver will cause problems

Sergeant Jennifer Callender (L) of the Illinois Air National Guard administers a vaccine for Pfizer Covid-19 to Virginia Persha on February 3, 2021 at a vaccination center at Triton College in River Grove, Ill.

Kamil Krzaczynski | AFP | Getty Images

Pfizer CEO Albert Bourla warned on Friday that waiving patent protection for Covid vaccines – a proposal just endorsed by President Joe Biden – would spark a global race for raw materials that would allow the safe and efficient manufacture of Covid- Shots at risk.

The Biden government said Wednesday it supports the limited intellectual property rule waiver in the service of expanding vaccine distribution to the lower-income countries currently hit by the pandemic.

But Bourla, whose company makes one of three vaccines approved for use in the United States, “categorically” believes the waiver will “cause more problems.”

“Right now, the infrastructure is not the bottleneck for us to produce faster,” wrote Bourla in a letter from a dear colleague published on LinkedIn. “The limitation is the lack of highly specialized raw materials needed to make our vaccine.”

Pfizer’s vaccine requires 280 different materials and components, sourced from 19 countries around the world, Bourla said. He claimed that companies with much less experience than Pfizer would compete for the same ingredients in making vaccines without patent protection.

“Currently, virtually every gram of the raw material produced is immediately delivered to our manufacturing facilities and is instantly and reliably switched to vaccines that are immediately shipped around the world,” wrote Bourla.

He predicted that the proposed waiver “threatens to disrupt the flow of raw materials”.

Albert Bourla, CEO of Pfizer, speaks after attending a press conference to monitor the production of the Pfizer-BioNtech COVID-19 vaccine at the factory of the US pharmaceutical company Pfizer in Puurs, Belgium, on April 23, 2021.

John Thys | Pool | Reuters

“It will create a mess for the critical inputs we need to make a safe and effective vaccine,” wrote Bourla.

“Companies with little or no vaccine manufacturing experience are likely hunting the very raw materials we need to scale our production, putting everyone’s safety at risk,” the CEO wrote.

The White House referred CNBC’s reach to Bourla’s post to the US sales representative’s office, which did not immediately respond to a request for comment.

The leaders of the World Trade Organization recently called on member states to reach an agreement on possible waivers for vaccination patents. But even with the support of the US, an agreement is hardly guaranteed, since the decisions of the WTO are based on consensus and require the consent of all 164 members.

Germany, a WTO member and the largest economy in Europe, spoke out against the waiver proposal on Thursday. BioNTech, which worked with Pfizer to develop the vaccine, is based in Germany.

Bourla on LinkedIn also expressed concern that potential vaccination waivers “will discourage others from taking great risks”.

“The latest rhetoric isn’t going to stop us from continuing to invest in science. However, I’m not sure if the same is true of the thousands of tiny biotech innovators who are totally dependent on access to capital from investors who just do investing provided their intellectual property is protected, “wrote the CEO.

PhRMA, the pharmaceutical industry advocacy group that includes Pfizer and Johnson & Johnson, another US vaccine company, described the waiver as “an unprecedented move that will undermine our global response to the pandemic and put safety at risk”.

Meanwhile, Moderna CEO Stephane Bancel, maker of the other U.S.-approved Covid shot, said he wasn’t concerned about the possible exemptions.

Categories
Health

U.S. Wager on Covid Vaccine Producer At the same time as Issues Mounted

U.S. Bet on Covid Vaccine Manufacturer Even as Problems Mounted

Due to the pandemic, most auditors drew their conclusions from documents and video tours where emergent employees checked camera angles, a former company employee said.

Johnson & Johnson reviewers said monitoring reports for bacteria or other contaminants were submitted four to six months late. According to AstraZeneca, Emergent has repeatedly relaxed the monitoring criteria so that they appear to be meeting them, using measures such as “historical averages”. But even then, it failed the tests, the report said.

In another audit, BARDA officials documented similar concerns and rated some of them as “critical”, including the risks of microbiological contamination. This designation is reserved for the most serious problems that pose an immediate and significant risk.

Emergent’s internal audit in July also found that the flow of workers and materials through the plant was not being adequately controlled “to avoid mix-ups or contamination.”

The reports reflected quality control deficiencies documented during an FDA inspection in April previously reported by The Associated Press that concluded that the facility was “not ready for commercial operation.”

Several audits underline how poorly the company was prepared for the enormous workload.

The Covid-19 projects required significantly more testing to ensure the materials remained stable. However, Emergent only had one employee who coordinated everything, as the BARDA audit showed. Emergent admitted at this point that its test system was “not ideal” and promised to train at least one more Emergent employee and hire a third. BARDA did not respond to requests for comment on its review or any of the others, except to state that it “worked with Emergent to resolve the issues raised during the FDA inspection.”

Another internal investigation in August found that Emergent approved four raw materials for AstraZeneca’s vaccine production without fully testing them. This type of link, known as conditional release of material, occurred an average of twice a week in October, internal logs show. The move was deemed necessary as the company operated with reduced production times, residue testing and met the requirements of Operation Warp Speed, the Trump administration’s crash vaccine development program. And while a manager “knowingly deviates from the standards,” the report said, batches of vaccines would not be released without quality and safety testing.

Categories
Politics

Regardless of Issues Within the Previous, Biden to Attempt Once more with ‘Inexperienced’ Stimulus

Despite Problems In the Past, Biden to Try Again with 'Green' Stimulus

Wind power has more than tripled in the past decade and now generates nearly 8 percent of the country’s electricity. Solar energy, which generated less than 1 percent of the country’s electricity in 2010, now generates about 2 percent and is growing rapidly. Economists generally agree that the Obama incentive, which brought these industries around $ 40 billion in credit and tax incentives, deserves some credit.

But experts also point to a fundamental problem with throwing money on climate change: it’s not a particularly effective way to cut emissions from the pollution caused by the warming of the planet. While Obama’s green spending created new construction jobs in the weather and helped turn a handful of boutique wind and solar companies into thriving industries, U.S. emissions of greenhouse gases that trap heat have remained roughly the same since 2010, five million tons per year are expected to stay at the same level for decades to come, unless there are new guidelines to enforce reductions like taxes or regulations.

Mr Obama had hoped to combine the recovery bill money with a new bill that would limit emissions to warm the planet, but those efforts died in Congress. His administration then passed emissions regulations, but these were blocked by the courts and withdrawn by the Trump administration.

The Restoration Act “was a success in creating jobs but failed to meet emissions reduction targets,” said David Popp, professor of public administration at Syracuse University and lead author of the National Bureau of Economics’ study on the green incentive of money. “And this new incentive alone will not be enough to reduce emissions.

“If you can’t combine it with a policy that forces people to cut emissions, a high spending bill won’t have much of an impact,” said Popp.

Frequently asked questions about the new stimulus package

How high are the business stimulus payments in the bill and who is entitled?

The stimulus payments would be $ 1,400 for most recipients. Those who are eligible would also receive an identical payment for each of their children. To qualify for the full $ 1,400, a single person would need an adjusted gross income of $ 75,000 or less. For householders, the adjusted gross income should be $ 112,500 or less, and for married couples filing together, that number should be $ 150,000 or less. To be eligible for a payment, an individual must have a social security number. Continue reading.

What Would the Relief Bill do for Health Insurance?

Buying insurance through the government program known as COBRA would temporarily become much cheaper. Under the Consolidated Omnibus Budget Reconciliation Act, COBRA generally lets someone who loses a job purchase coverage through their previous employer. But it’s expensive: under normal circumstances, a person must pay at least 102 percent of the cost of the premium. Under the Relief Act, the government would pay the full COBRA premium from April 1 to September 30. An individual who qualified for new employer-based health insurance elsewhere before September 30th would lose their eligibility for free coverage. And someone who left a job voluntarily would also be ineligible. Continue reading

What would the child and dependent care tax credit bill change?

This loan, which helps working families offset the cost of looking after children under the age of 13 and other dependents, would be significantly extended for a single year. More people would be eligible and many recipients would get a longer break. The bill would also fully refund the balance, which means you could collect the money as a refund even if your tax bill were zero. “This will be helpful to people on the lower end of the income spectrum,” said Mark Luscombe, chief federal tax analyst at Wolters Kluwer Tax & Accounting. Continue reading.

What changes to the student loan are included in the invoice?

There would be a big one for people who are already in debt. You wouldn’t have to pay income taxes on debt relief if you qualify for loan origination or cancellation – for example, if you’ve been on an income-based repayment plan for the required number of years, if your school cheated on you, or if Congress or the President whisper $ 10,000 debt gone for a large number of people. This would be the case for debts canceled between January 1, 2021 and the end of 2025. Read more.

What would the bill do to help people with housing?

The bill would provide billions of dollars in rental and utility benefits to people who are struggling and at risk of being evicted from their homes. About $ 27 billion would be used for emergency rentals. The vast majority of these would replenish what is known as the Coronavirus Relief Fund, which is created by the CARES Act and distributed through state, local, and tribal governments, according to the National Low Income Housing Coalition. This is on top of the $ 25 billion provided by the aid package passed in December. In order to receive financial support that could be used for rent, utilities and other housing costs, households would have to meet various conditions. Household income must not exceed 80 percent of area median income, at least one household member must be at risk of homelessness or residential instability, and individuals would have to be due to the pandemic. According to the National Low Income Housing Coalition, assistance could be granted for up to 18 months. Lower-income families who have been unemployed for three months or more would be given priority for support. Continue reading.

But, he added, “Spending money is politically easier than enacting emission-reduction policies.” If this “sets up the energy industry so that it is ultimately cheaper to cut emissions, it could create more political support for it” by making laws or regulations less painful, he said.

Categories
Business

How Texas’ robust winter uncovered U.S. energy grid issues

How Texas' tough winter exposed U.S. power grid problems

Texas had a rough winter in 2021.

In mid-February, when temperatures dropped in the single digits, demand for electricity hit a record high across Texas. The supply was running low, causing the state’s utility operator to introduce rolling blackouts. At the height of the crisis, more than 4.5 million customers lost electricity. The unusual winter storm caused neighboring states like Louisiana, Oklahoma, Arkansas, and Kansas to also impose rolling power outages.

Texas residents shivered from the cold as the outages lasted for days. You have lost access to water. Some turned their cars on in their garages to keep warm and then died of carbon monoxide poisoning.

The historic collapse was a wake-up call – if the Texas power grid was so fragile, what about the rest of the United States? According to Climate Central, the US has seen weather-related blackouts have increased by 67% since 2000. Part of the problem is aging infrastructure. Most of today’s power grid was built in the 1950s and 1960s with the hope that it would take 50 years.

Check out the video above to find out what happened in the Texas power outage and how it’s a warning sign on the US power grid.

Categories
Health

All the problems and issues the shot has confronted

All the issues and problems the shot has faced

The Covid vaccine Petra Moinar prepares syringes with the AstraZeneca vaccine before it is administered on March 8, 2021 at the Battersea Arts Center in London, England.

Chris J Ratcliffe | Getty Images News | Getty Images

AstraZeneca’s Covid shot, dubbed the “Vaccine for the World”, has had high hopes since its inception. However, unlike other coronavirus vaccines, the shot developed by AstraZeneca and the University of Oxford has been plagued from problem to problem.

AstraZeneca’s problems began almost as soon as preliminary trial data was released and have continued ever since.

The drug maker “seems to be having a real PR problem in the US and Europe,” Sunaina Sinha Haldea, managing partner of Cebile Capital, told CNBC on Thursday, warning that its “PR problem is raising confidence in the vaccine outdoors could undermine “the UK”

Here is a timeline of all the issues that AstraZeneca has encountered over the past year:

November 2020 – process data dispute

AstraZeneca released an interim clinical trial analysis showing that its Covid vaccine has an average of 70% effectiveness in protecting against the virus. The result was initially welcomed by the global community, which was already supported by positive results for the recordings by Moderna and Pfizer-BioNTech.

Upon further examination, it became clear that the 70% figure came from the combination of the analyzes of two separate dosage regimens within the experiments. One dosing regimen showed 90% effectiveness when subjects received half a dose followed by a full dose at least a month apart. The other showed 62% effectiveness when given two full doses at least one month apart.

AstraZeneca admitted that the half-dose regimen was a mistake, but described it as a “useful mistake” and a “coincidence”. However, it has been criticized by US experts, and AstraZeneca’s chance announcement of the bug was arguably the start of its reputational problems.

January 2021 – delivery dispute

In early January, the UK began rolling out the AstraZeneca-Oxford University vaccine. It had an added bonus for the country: the majority of its cans would be made in the UK.

It wasn’t long, however, before a dispute over supplies with the European Union began after reports that the drug maker was failing to make its contracted supplies to the bloc.

A very public dispute over contracts erupted, sparking a history of bitter relations between the EU and the UK and the Anglo-Swedish drug maker. The EU has made waves suggesting AstraZeneca is rerouting supplies from the UK to the block

January 2021 – Effectiveness in disputes over 65 years of age

90 year old Margaret Keenan is greeted by staff as she returns to her ward after becoming the first patient in the UK to receive the Pfizer / BioNtech COVID-19 vaccine at the University Hospital Coventry, UK December 8, 2020.

Jacob King | Reuters

March 2021 – Dispute over blood clots

Late March 2021 – US data dispute

AstraZeneca worries continued this week – even though they started at a high level for the drug maker. On Monday, the results of a large U.S. study showed the vaccine was safe and highly effective, raising hopes that it could soon seek U.S. approval for the shot.

However, on Tuesday, a US health agency announced that AstraZeneca may have included “out of date” information in its study results, casting doubts about published efficacy rates.

AstraZeneca responded that the numbers released Monday were “based on a pre-determined interim analysis with a February 17th data deadline,” saying it would share its primary analysis within 48 hours of the most recent efficacy data.

On Wednesday, the company released updated Phase 3 trial data for its Covid-19 vaccine, showing that its vaccine is 76% effective – slightly lower than the 79% rate published on Monday.

What’s next for AstraZeneca?

The problems facing AstraZeneca could continue as EU leaders virtually meet on Thursday to discuss possible vaccine export bans that could hit the drug maker. However, the EU and the UK said on Wednesday that they wanted to find a “win-win” solution to the supply problem.

The negative coverage of AstraZeneca has led some viewers (and certainly the UK media) to point out that post-Brexit, the vaccine has become a target for negative sentiment in Europe directed against the UK. It has also been suggested that the shot could be the victim of vaccine nationalism in the US, where competing shots came from Moderna and Pfizer-BioNTech (although BioNTech is a German company).

Regardless of the underlying causes, AstraZeneca’s reputation has been badly damaged.

As Shore Capital health analysts said in a note Thursday, “Any confusion about results can quickly turn into concerns about the safety and effectiveness of vaccines, even if those concerns are not based on solid evidence.”

The AstraZeneca vaccine was “particularly badly affected by confusion about the data reported. Importantly, this confusion can lead to an erosion of trust in vaccines, which are proven, life-saving drugs.”

Categories
World News

Suez Canal cargo ship blockage might trigger issues for the globe

Suez Canal cargo ship blockage could cause problems for the globe

The stranded container ship Ever Given, one of the largest container ships in the world, was seen aground in Egypt’s Suez Canal on March 25, 2021.

Suez Canal Authority | Reuters

The gigantic cargo ship that is stuck in the Suez Canal and blocking traffic at one of the most important choke points for sea trade in the world is not yet ready to break free.

The Ever Given, a 220,000-ton mega-ship with a capacity of almost a quarter mile and a capacity of 20,000 containers, ran aground after being blown by strong winds as it entered Egypt’s Suez Canal from the Red Sea. The passage, which is home to up to 12% of the world’s maritime trade and through which 50 container ships normally pass per day, is completely blocked.

Tugs and dredgers are currently working on removing the ship, which has been stalled since Tuesday evening. But the operation could take weeks, one of the executives involved warned.

“Although we believe and hope that the situation will improve shortly, there is a risk that the ship will break,” JP Morgan strategist Marko Kolanovic wrote in a note on Thursday. “In this scenario, the channel would be blocked for an extended period of time, which could lead to significant disruptions in world trade, skyrocketing shipping rates, a further surge in energy resources and an increase in global inflation.”

The crisis is another blow to the global supply chain after a brutal year of delays, bottlenecks and price pressures due to the coronavirus pandemic.

What does this mean for world trade?

The shipping delays can affect everything from clothes and shoes you ordered online to fitness equipment, electronics, groceries, and power supplies – which means gas prices could go up too.

“The blocking of containers in the Suez Canal to further shake global supply chains and raise prices in the face of pent-up demand,” said JPMorgan analysts in a research report on Thursday.

The artificial Suez is 120 miles long and an important transit point between east and west. And the 20,000 ships that pass annually transport everything from oil and gas to machine parts and consumer goods.

While it is still early to say how the full impact of the tanker crisis will play out, the bank anticipates that in the near future, the blockade will likely add to the supply strains in the industry, already caused by ongoing supply chain bottlenecks the form of congestion in the port and the lack of ships and containers due to Covid-19 are hindered.

Ships have to divert to completely different routes, “which will lead to longer journey times and further delays,” wrote JPMorgan.

And those delays could be more than 15 days for many ships, the alternative of which is to circumnavigate the Cape of Good Hope on the southern tip of Africa, which analysts say would increase shipping times by up to 30%.

“The immediate effects of delays in the canal will focus on Euro-Asian trade, delaying the already disrupted supply chains affecting the supply of oil and refined products,” ING senior economist Joanna Konings wrote in a Wednesday Customer notification.

Effects on Crude Oil Prices

The Ever Given disaster is already having an impact on oil prices.

The news of the Suez Blockade attracted buyers and, along with other economic data, helped the one-month futures contract on the international benchmark Brent Crude Oil “posted its largest one-day gain in nearly a year,” according to Arctic Securities on Wednesday $ 64.41 closed “although it lost some of those gains through Thursday.

Meanwhile, between 5% and 10% of all marine oil is transported through the Suez, which means that for every day the ship gets stuck, another 3 to 5 million barrels of oil per day will be delayed. Several tankers carrying jet fuel and gas oil are also being held up on the route between the Persian Gulf and Europe, as well as empty tankers crossing to pick up North Sea oil, S & P Platts reported on Thursday.

A graphic that halts shipping around the Suez Canal after the Ever Given ship got stuck in the canal.

Source: MarineTraffic

The canal is also a transit point for around 8% of the world’s liquefied natural gas (LNG), and a prolonged interruption could disrupt flows mainly to the European market.

Any price effect is likely to be brief, however, says Peter Sutherland, president of Houston-based energy investment firm Henrietta Resources LLC.

“It won’t have a lasting impact on prices, but it will help provide support in the run-up to the OPEC + meeting,” Sutherland told CNBC.

“The risk premium in the oil markets will likely be short-lived, but channel support has still managed to change the market narrative.”

The winners

The canal blockade is certainly not bad news for everyone – the spot freight rates will continue to rise due to the pent-up demand and make money for the operators, say market observers.

“A prolonged closure of the Suez Canal would see container shipping as the greatest beneficiary, while tankers, dry matter and air freight may also have higher rates,” wrote JPMorgan, describing the tightening of shipping rates as an “upside risk”.

Satellite images of the container ship Ever Given are stuck in the Egyptian Suez Canal.

Source: European Space Agency’s Sentinel-2 Satellite

Who will benefit most from it? JP Morgan highlights Asian liners, saying they expect higher spot freight rates despite higher bunker costs due to longer rerouted trips and increasing congestion. “In our view, it is expected that this will have a positive impact on the bottom line of the Asian lines rather than hurting profitability,” the bank wrote.

Bank of America analysts agree. “A Suez closure of a few weeks would be very positive for spot freight rates – by effectively reducing supply by increasing the sailing distance over the Cape of Good Hope by 20-30%,” she wrote in her note on Thursday.

Risks and weak points grow

Meanwhile, the Suez Canal blockade will “add to an already rising risk premium for oil and refined products in the Middle East,” said Torbjorn Soltvedt, chief MENA analyst at Verisk Maplecroft, highlighting the increased risk of oil rig attacks amid regional tensions emerged.

The uncertainty about the length of the blockade “creates a window of opportunity for state and non-state actors to try to maximize the impact of attacks on tankers and energy infrastructure in the Persian Gulf and Red Sea,” he warned.

Cargo ship “Ever Given” is stuck and blocking traffic in the Suez Canal

Source: Reuters

Most analysts expect the situation to improve within the week. “However, the disorder could be prolonged if complications or torso damage occurs,” Bank of America wrote on Thursday. If the traffic is cleared at some point, the ships arrive at their ports behind schedule, causing further congestion.

Nevertheless, the bank writes: “A blockade of a few days would be largely manageable for container shipping – possibly associated with additional fuel costs, as the shipping companies accelerate their services to make up for lost time.”

The whole fiasco underscores the fragility of the trading network that the world really relies on, Sutherland says.

“Coupled with the recent attacks on Saudi assets, it is a reminder of the many vulnerabilities in the global oil and gas supply chain.”

Categories
Business

Challenges and issues in vaccine technique

Challenges and problems in vaccine strategy

Pharmacy students Anne Brandt (l) and Sarah Schulz are preparing six syringes from a vial with the SARS-CoV-2 coronavirus vaccine from Biontech / Pfizer for vaccination of medical staff at the Leipzig University Hospital. There are currently more requests for vaccination appointments than can currently be offered.

Image Alliance | Image Alliance | Getty Images

Since Germany started its vaccination campaign together with the rest of the EU at the end of December, it has encountered a number of logistical challenges.

Now, nearly a month after the program began, the slow progress made by some German lawmakers and health professionals is causing frustration and concern.

Health Minister Jens Spahn had targeted 300,000 vaccinations per day, but the country has not yet achieved this. Data from the health department, the Robert Koch Institute, released on Tuesday showed that just over 62,000 vaccinations (most of which were first doses) had been given in the past 24 hours.

Since the start of vaccinations in Germany in all 16 federal states on December 27, almost 1.2 million people in Germany (the priority groups are currently healthcare workers, residents of nursing homes and employees, as well as the elderly) have received a first dose of the coronavirus Vaccine and nearly 25,000 have received their second dose.

In contrast, the UK, which became the first country in the world to approve and introduce the Pfizer BioNTech vaccine (partly developed in Germany), and the Oxford-AstraZeneca University candidate started its Covid vaccination program in early December to date, over 4 million people have been vaccinated to date vaccinated with their first dose of vaccine (over 450,000 had their second dose) and by the end of last week they were being vaccinated over 300,000 vaccinations per day.

Wide range of problems

The EU had a policy of buying coronavirus vaccines as a block, but some countries, including Germany, also made their own additional purchase agreements.

Nonetheless, supply problems were already a problem at the beginning of the vaccination campaign in Germany, as vaccines were not available in certain centers and other difficult logistical problems arose with the vaccination of his priority groups such as the elderly. This has resulted in inconsistent vaccine delivery performance from state to state within the country.

Dr. Stefan HE Kaufmann, a renowned immunologist and microbiologist in Germany and founding director of the Max Planck Institute for Infection Biology in Berlin, told CNBC on Tuesday that the vaccination process was associated with challenges from the start.

“The number one priority (in the vaccination campaign) is currently the elderly and people with serious illnesses, especially in children’s homes. This process is ethical, but very time-consuming. It also includes health care workers and medical staff in nursing homes and hospitals. Apparently some of the nursing home staff are hesitant about vaccination, “he noted.

Fenna Martin (C) vaccinates Marielotte Kilian (L), 87, and Richard Kilian (R), 86, against Covid-19 in the vaccination center, which was installed on January 19, 2021 at the convention center in Wiesbaden, western Germany, which opened in the western state of Hesse its first six vaccination centers in the midst of the novel coronavirus.

ARNE DEDERT | AFP | Getty Images

So far, only the vaccines developed by Pfizer, BioNTech and Moderna have been approved for block use by the European Medicines Agency. The easier to store and transfer (and cheaper) candidate from AstraZeneca and Oxford University has not yet been approved.

When it comes to introducing vaccines, time is of the essence, especially in cases where there is an increase due to the more transmissible mutations. Nevertheless, Germany has registered fewer cases than many of its neighbors and has recorded just over 2 million infections to date. The death toll stands at 47,958.

A key problem for both the UK and the EU is that supply cannot meet current demand for vaccines, and Germany was no exception. Early reports of people struggling to get a vaccination appointment because doses are tight. However, vaccine manufacturers have promised to ramp up production and deliver millions more doses over the next few weeks and months.

In the meantime, however, “the doses secured for immediate use are insufficient,” said Kaufmann.

“While so-called vaccination centers have been set up throughout Germany, vaccines for a rapid maximum vaccination rate are currently lacking in these centers. (The) hope is that the process will be accelerated after the difficult and time-consuming vaccination has been achieved (at nursing homes),” he said and noted that the speed of the German vaccination campaign “would have been faster if more doses of BioNTech and Moderna had been secured”.

“In my opinion, everything must be done to get more doses for immediate or short-term use. This is all the more important as mutant strains that could evade vaccine-induced immune responses are becoming more common,” he warned.

Political criticism

Germany is not the only one who sees a slow start to its vaccination campaign. The European Commission has been criticized across the EU for failing to procure enough vaccines for the block.

Florian Hense, European economist at Berenberg, told CNBC that the approval and procurement process has left the EU behind, or at least behind, other countries like the UK and the US when it comes to sourcing vaccines.

“Since the EU negotiated and approved vaccinations with pharmaceutical companies on behalf of its member states, the German vaccination campaign was always ‘un-German’, regardless of what you associate with the term,” he told CNBC on Monday.

Elderly people who have just been vaccinated against COVID-19 wait briefly for side effects before leaving the vaccination center at the Messe Berlin exhibition center on the opening day of the center during the second wave of the coronavirus pandemic on January 18, 2021 in Berlin, Germany. The center is the third to open in Berlin. Three more are to be opened in the coming weeks as soon as supplies of the Pfizer / BioNTech and Moderna vaccines pick up speed.

SEAN GALLUP | AFP | Getty Images

“I suspect that the EU’s later approval delayed the start of vaccinations and has since limited the pace of vaccinations per day as vaccinations arrived in the EU more slowly than the UK, US (per capita)” “

Needless to say, other parliamentarians have criticized the government’s overall strategy. Dr. Janosch Dahmen, doctor and German MP for the Greens, told CNBC that he was “very concerned because Germany is already behind”.

“The progress of the vaccination campaign is far too slow and one of the reasons is the supply bottleneck. The more pressing problem, however, is that the vaccination infrastructure shows several problems, mainly staff shortages, distribution problems in the federal states and much more too much of a central approach,” he said.

“As a doctor and a politician, I am very concerned about the situation here and, apart from all the efforts we need to make to make the nationwide vaccination campaign more effective, we need to build bridges through testing, self-testing and testing, and we need to put more effort into contact tracing which is another important part of fighting this pandemic, “said Dahmen.

Categories
Health

6 Months Later, Covid Survivors Stricken by Well being Issues

6 Months Later, Covid Survivors Plagued by Health Problems

Most of the symptoms in the Wuhan report were slightly more common in women. 81 percent reported at least one health problem, compared with 73 percent for men.

Reports of other respiratory illnesses like the 2003 outbreak of SARS, another type of coronavirus, suggest that some Covid survivors may experience after-effects for months or years. Most SARS patients recovered physically, but the researchers found that many had “worrying depression, anxiety, and post-traumatic symptoms” a year later.

Commenting on the Lancet study, researchers from Italy wrote that 38 percent of SARS survivors had decreased the flow of oxygen from their lungs 15 years later, adding that “Evidence of previous coronavirus outbreaks suggests some degree Lung damage could persist ”.

While people hospitalized for Covid may have more serious or prolonged physical problems, increasing evidence shows that even people who have never been hospitalized may have residual symptoms. Many of these patients seek care in the post-Covid clinics in the United States.

A recent survey by a patient-led research team included 3,762 participants, mostly women, from 56 countries, most of whom had not been hospitalized. Nearly two-thirds said they had symptoms for at least six months, with most saying they were tired and their symptoms got worse after physical or mental exertion, the report, which was not peer-reviewed. More than half of those affected said they had “cognitive dysfunction” with brain fog or difficulty thinking or concentrating.

Dr. Peluso noted that most Wuhan patients were hospitalized in the first half of 2020 and most were not treated with newer therapies like remdesivir or dexamethasone. It is therefore unclear whether people who received these treatments would now receive the same level of long-term term complications.

Even so, he and other doctors said the study’s portrait of persistent symptoms is true. Dr. Ferrante said that in the post-Covid recovery program where she treats patients, “pretty much everyone I see reports impaired physical or cognitive function, or both.”

[Like the Science Times page on Facebook. | Sign up for the Science Times newsletter.]